Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

(2016) Frederick C. Lahser et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

(2015) Stefan Zeuzem et al.   ANNALS OF INTERNAL MEDICINE

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.

(2015) Maria Buti et al.   CLINICAL INFECTIOUS DISEASES

901f Efficacy and Safety of Grazoprevir/Elbasvir ± Ribavirin (RBV) for 12 or 16 Weeks in Patients With HCV G1, G4, or G6 Infection Who Previously Failed Peginterferon/RBV: C-EDGE Treatment-Experienced Trial

(2015) Paul Y Kwo et al.   GASTROENTEROLOGY

Sofosbuvir for treatment of chronic hepatitis C

(2015) Sarah Kattakuzhy et al.   Hepatology International

P0776 : Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients

(2015) E. Gane et al.   JOURNAL OF HEPATOLOGY

P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial

(2015) P. Kwo et al.   JOURNAL OF HEPATOLOGY

P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection

(2015) A. Brown et al.   JOURNAL OF HEPATOLOGY

O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)

(2015) I.M. Jacobson et al.   JOURNAL OF HEPATOLOGY

O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks

(2015) F. Poordad et al.   JOURNAL OF HEPATOLOGY

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

(2015) Xavier Forns et al.   JOURNAL OF HEPATOLOGY

Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial

(2015) M. Lagging et al.   JOURNAL OF VIRAL HEPATITIS

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Mark Sulkowski et al.   LANCET

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Eric Lawitz et al.   LANCET

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

(2015) David Roth et al.   LANCET

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

(2015) Jürgen K Rockstroh et al.   Lancet HIV

The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis

(2014) Michael P. Manns et al.   GASTROENTEROLOGY

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

(2014) Mark S. Sulkowski et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hepatitis C virus NS5A inhibitors and drug resistance mutations

(2014) Shingo Nakamoto   WORLD JOURNAL OF GASTROENTEROLOGY

Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity

(2013) Craig A. Coburn et al.   ChemMedChem

Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis

(2013) Weiwei Xue et al.   Journal of Chemical Information and Modeling

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

(2012) Vincenzo Summa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

(2012) Steven Harper et al.   ACS Medicinal Chemistry Letters